[{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ab8","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Not Applicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The University of Pittsburgh School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"Nanobody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"The University of Pittsburgh School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Not Applicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"SNAP-CAR T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ University of Pittsburgh"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"Protein synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The University of Pittsburgh School of Medicine \/ University of Pittsburgh","highestDevelopmentStatusID":"7","companyTruncated":"The University of Pittsburgh School of Medicine \/ University of Pittsburgh"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ University of Pittsburgh"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"}]

Find Clinical Drug Pipeline Developments & Deals by The University of Pittsburgh School of Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 di...

                          Brand Name : GPX-002

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 18, 2023

                          Lead Product(s) : GPX-002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Genprex

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : University of Pittsburgh grants Genprex a preclinical technology that transforms macrophages, complementary to the GPX-002 diabetes technology. Novel infusion process uses an endoscope and an AAV vector with a glucagon promoter to deliver the Pdx1 + MafA...

                          Brand Name : GPX-002

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 05, 2023

                          Lead Product(s) : GPX-002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : Genprex

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Diabetic mice studies have shown that GPX-002, a gene therapy for diabetes, restored normal blood glucose levels for an extended period of time, which could translate to decades in humans.

                          Brand Name : GPX-002

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 15, 2022

                          Lead Product(s) : GPX-002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Genprex

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Preclinical research in a syngeneic solid tumor mouse model shows that I/ONTAK (E7777 or denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 therapy.

                          Brand Name : I/ONTAK

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 22, 2022

                          Lead Product(s) : Denileukin Diftitox,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Citius Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Current SNAP-CAR T therapies are designed to target specific tumor antigens that correspond to a specific cancer indication. This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies.

                          Brand Name : SNAP-CAR T Cell Therapy

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 21, 2022

                          Lead Product(s) : SNAP-CAR T Cell Therapy,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Coeptis Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The treatment, dubbed PiN-21, could offer an affordable, needle-free option for treating early infections of SARS-CoV-2—the novel coronavirus behind COVID.

                          Brand Name : PiN-21

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          May 26, 2021

                          Lead Product(s) : nanobody

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Cell Biology and Developmental Biology in University of Pittsburgh School of Medicine and Astellas will work jointly to evaluate and optimize the drug candidates with an aim to provide new treatment options to help recover and maintain vision in dry AMD ...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 24, 2020

                          Lead Product(s) : AAV-based gene therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The researchers reported in the journal Cell that Ab8 is highly effective in preventing and treating SARS-CoV-2 infection in mice and hamsters. In mice and hamsters, Ab8 proved effective in preventing and treating the disease; the journal Cell published ...

                          Brand Name : Ab8

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 14, 2020

                          Lead Product(s) : Ab8

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank